Success at Bangalore Bio

Mawdsleys’ clinical trials division, Wellspring, was launched onto the international market recently as they attended Bangalore Bio, India’s premier biotechnology event.

Nick Hill, Mawdsleys’ Unlicensed Medicines Manager and Catherine Harper, Wellspring’s Clinical Trials Business Manager teamed up with a remit to demonstrate to pharma and biotech companies how the group can help them go “full circle” from clinical trials to pre-launch.

Catherine Harper explains: “One of the main purposes of attending the event was to set up exclusive partnerships with pharma companies to be the sole supplier of their pre-launch products. Prior to our visit to India, we had incredible support from the UKTI (UK Government’s trade and investment division) who set up appointments for us with interested companies in the Indian biotech and CRO industries in advance. During our seven day visit, we had the opportunity to present to the decision makers of about 60 companies and were literally bombarded with people wanting to talk to us!”

Unlicensed Medicines Manager, Nick Hill, adds: “The UKTI also arranged visits to companies in Mumbai and Bangalore and we saw first hand evidence of the massive boom in clinical trial business and allied services in India. We also managed to visit clinical research companies and manufacturing plants which reassured us of the very high standards to which companies are working there.

“All in all, Bangalore Bio was a huge success for all concerned and we will certainly be making sure that we capitalise on all the excellent contacts we made with the pharma industry in India.”